Single-center, Randomized, Open Label, Negative-controlled Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC(Autologous Adipose Tissue Derived Mesenchymal Stem Cells) After High Tibial Osteotomy Compared to Negative Control in the Osteoarthritis Patients.
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors BioStar
- 28 Jan 2021 Status changed from active, no longer recruiting to completed.
- 03 Jun 2019 Planned End Date changed from 1 Mar 2019 to 20 Apr 2020.
- 03 Jun 2019 Planned primary completion date changed from 30 Dec 2018 to 22 Feb 2020.